Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Successful Completion of PrimaryBid Offer

29 May 2018 07:00

RNS Number : 4381P
Mereo BioPharma Group plc
29 May 2018
 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE PROHIBITED BY ANY APPLICABLE LAW.

 

 

29 May 2018

Mereo BioPharma Group plc

 ("Mereo" or the "Company")

 

Successful Completion of PrimaryBid Offer

 

Mereo BioPharma Group plc (AIM: MPH), announced on 25 May 2018 the launch of an offer via PrimaryBid (the "Offer") to broaden its shareholder base by accessing additional retail investors via the Offer.

 

The Company has placed 50,076 ordinary shares of 0.3 pence each ("Ordinary Shares") via PrimaryBid at 300p per Ordinary Share. The Company will allot and issue 50,076 new Ordinary Shares ("New Ordinary Shares") pursuant to the Offer. Application will be made for the New Ordinary Shares to be admitted to trading on AIM, which is anticipated to occur on or around 1 June 2018 ("Admission"). The New Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.

 

Total Voting Rights

 

Following Admission, the Company will have 71,145,050 Ordinary Shares in issue with voting rights. The Company does not hold any Ordinary Shares in treasury and accordingly there are no voting rights in respect of any treasury shares. Therefore, the total number of voting rights in the Company with effect from Admission will be 71,145,050. This figure may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Enquiries:

 

Mereo BioPharma Group plc

+44 (0)333 023 7300

Denise Scots-Knight, Chief Executive Officer

Richard Jones, Chief Financial Officer

Cantor Fitzgerald Europe (Nominated Adviser)

+44 (0)20 7894 7000

Phil Davies

Will Goode

PrimaryBid

Dave Mutton

+44 (0)20 7491 6519

FTI Consulting (Public Relations Adviser)

Simon Conway

+44 (0)20 3727 1000

Brett Pollard

 

The person responsible for arranging the release of this information on behalf of the Company is Charles Sermon, Company Secretary.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROIUWVRRWVAVUUR
Date   Source Headline
15th Dec 20206:22 pmRNSAIM Delisting
30th Nov 20207:00 amRNSKey Dates for AIM Delisting
23rd Nov 202012:00 pmRNSMereo appoints Suba Krishnan
16th Nov 202012:00 pmRNSVirtual R&D Day
11th Nov 20207:00 amRNSCancellation of AIM admission
10th Nov 202012:00 pmRNSStifel 2020 Virtual Healthcare Conference
20th Oct 202012:00 pmRNSAppointments of CFO and SVP
19th Oct 202012:00 pmRNSTIGIT IND FDA Clearance
12th Oct 20201:44 pmRNSPDMR Notification
9th Oct 20204:05 pmRNSDirector/PDMR Shareholding
7th Oct 202012:00 pmRNSRegistration Statement Filed with US SEC
29th Sep 202012:00 pmRNSInterim Results for 6 months ended June 30, 2020
28th Sep 20203:21 pmRNSResult of General Meeting
28th Sep 202012:00 pmRNSChanges to Board of Directors
24th Sep 202012:00 pmRNSFDA Rare Pediatric Disease Designation
16th Sep 20201:00 pmRNSNotice of Interim Results
4th Sep 20207:00 amRNSNotice of General Meeting
25th Aug 202012:00 pmRNSInitiation of COVID-19 Respiratory Disease Trial
14th Aug 20207:00 amRNSPDMR Notification
13th Aug 20207:00 amRNSNotification of PDMR Dealing
6th Aug 20207:00 amRNSAppointment of Nominated Adviser & Broker
5th Aug 20207:00 amRNSDirector Dealing
6th Jul 20203:59 pmRNSHolding(s) in Company
6th Jul 20209:34 amRNSBlock Listing Application
30th Jun 20201:39 pmRNSResult of General Meeting
30th Jun 202012:00 pmRNSCSO and SVP appointments
29th Jun 20203:56 pmRNSResult of Annual General Meeting
22nd Jun 20204:33 pmRNSHolding(s) in Company
22nd Jun 202011:06 amRNSSecond Price Monitoring Extn
22nd Jun 202011:00 amRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSFinal Results for the year ended December 31, 2019
11th Jun 20204:41 pmRNSSecond Price Monitoring Extn
11th Jun 20204:36 pmRNSPrice Monitoring Extension
10th Jun 20205:30 pmRNSHolding(s) in Company
9th Jun 20204:45 pmRNSNotice of General Meeting
8th Jun 20205:56 pmRNSHolding(s) in Company
8th Jun 20205:18 pmRNSHolding(s) in Company
8th Jun 20203:20 pmRNSHolding(s) in Company
5th Jun 20203:55 pmRNSHolding(s) in Company
5th Jun 202012:49 pmRNSHolding(s) in Company
4th Jun 20202:05 pmRNSSecond Price Monitoring Extn
4th Jun 20202:00 pmRNSPrice Monitoring Extension
4th Jun 20207:00 amRNSCompletion of $70 Million Private Placement
3rd Jun 20209:05 amRNSSecond Price Monitoring Extn
3rd Jun 20209:00 amRNSPrice Monitoring Extension
27th May 202012:00 pmRNSNotice of Annual General Meeting
22nd May 202012:00 pmRNSAnnual General Meeting
21st May 20204:18 pmRNSHolding(s) in Company
27th Mar 202012:00 pmRNSBusiness Update and Directorate Change
6th Mar 20207:00 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.